LMAT — LeMaitre Vascular, Inc.

Summary of LeMaitre Vascular, Inc. Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Organic Sales Growth: 12% in Q3; 14% excluding catheters.
• Total Revenue: Reported revenue growth of 11%, impacted by $1.3 million from Aziyo distribution exit.
• Gross Margin: Reported at 75.3%, with adjusted gross margin at 70.8%, a 300 basis point increase year-over-year.
• Operating Income: Reported operating income of $20.3 million, with an operating margin of 33%. Adjusted operating income was $16.9 million, up 29%, resulting in an adjusted operating margin of 28%.
• Net Income: Reported net income of $17.4 million; adjusted net income increased 27% to $14.2 million.
• Earnings Per Share (EPS): Reported diluted EPS of $0.75; adjusted EPS of $0.62, up 27%.
• Cash Position: Ended Q3 with $343.1 million in cash and securities, generating $28.8 million in cash from operations.

2. Strategic Updates and Business Highlights:

• Product Performance: Strong sales in Grafts (up 23%) and Shunts (up 18%). Artegraft sales increased significantly, with Q3 sales of $1.4 million and projected Q4 sales of $2 million.
• International Expansion: Received approvals for RestoreFlow in Germany and expect further approvals in Canada and Ireland in 2026. A new distribution center in Dublin has been leased to support growth.
• Sales Force Management: Ended Q3 with 152 sales reps, aiming for 165 by year-end. Performance-based reductions led to the layoff of 8 reps, with 23 open positions for new hires.

3. Forward Guidance and Outlook:

• 2025 Revenue Guidance: Raised to $248 million, reflecting 13% growth.
• Operating Income and EPS Guidance: Adjusted operating income expected at $63.7 million (up 22%) with an adjusted operating margin of 26%. Adjusted EPS guidance raised to $2.37, a 22% increase over 2024.
• Q4 Guidance: Anticipating 40% operating income growth and a 29% operating margin.

4. Bad News, Challenges, or Points of Concern:

• Catheter Recall Impact: The recall led to front-loaded sales in Q2, negatively affecting Q3 and expected to continue impacting Q4 growth.
• APAC Market Struggles: Notable challenges in the APAC region, attributed to management changes and lower sales performance.
• FDA Warning Letter: Received for the New Jersey Artegraft facility related to quality management, though it has not disrupted operations.
• Currency Impact: A stronger U.S. dollar has negatively affected Q4 revenue guidance by approximately $600,000.

5. Notable Q&A Insights:

• Revenue Guidance Adjustments: The decrease in organic growth expectations was attributed to the catheter recall, weaker performance in Europe and APAC, and currency fluctuations.
• Pricing Strategy: 55% of North American revenue is now subject to price floors, indicating a strategic focus on maintaining pricing power in niche markets.
• R&D Spending: Current R&D spending is around 6%, with expectations to increase as the company seeks regulatory approvals and product development.
• Sales Growth Composition: The growth is more from existing accounts in North America, while new accounts are contributing more significantly in Europe and APAC.
• Market Dynamics: The exit of BARDA from the carotid shunt market has allowed for increased market share and pricing flexibility in Europe.

This summary encapsulates the key points from the earnings call, highlighting both the positive developments and the challenges faced by LeMaitre Vascular, Inc. in Q3 2025.